- Merck & Co Inc’s (NYSE:MRK) Phase 3 KEYNOTE-921 trial of Keytruda combined with chemotherapy (docetaxel) did not meet its dual primary endpoints of overall survival (OS) and radiographic progression-free survival (rPFS) for metastatic castration-resistant prostate cancer (mCRPC).
- The study showed modest trends toward improving both OS and rPFS for patients who received Keytruda + chemo combo than chemotherapy alone; however, these results did not meet statistical significance.
- Separately, Merck and Eisai Co Ltd’s (OTC:ESALY) Phase 3 LEAP-002 trial of Keytruda plus Lenvima did not meet its dual primary endpoints of OS and progression-free survival (PFS) in unresectable hepatocellular carcinoma (uHCC).
- The median OS of the Lenvima monotherapy arm was longer than that observed in previously reported clinical trials evaluating Lenvima monotherapy in uHCC.
- The safety profile of Keytruda was consistent with that observed in previously reported studies.
- Price Action: MRK shares are up 0.43% at $87.99 during the premarket session on the last check Wednesday.
Morgan Stanley Maintains Equal-Weight on Avient, Lowers Price Target to $50
Morgan Stanley analyst Angel Castillo maintains Avient (NYSE:AVNT) with a Equal-Weight and lowers the price target from $63 to $50.
